2025年来,mRNA领域颇有“复苏”的迹象。6月底,艾伯维宣布斥资21亿美元收购体内CAR-T疗法公司Capstan Therapeutics;而BioNTech、Moderna等更早入局的企业,也已布局了成熟的mRNA疫苗的药物设计和递送技术等研发平台,探索肿瘤疫苗等产品的研发,进展快者已进入二期临床阶段。相较之下,国内企业在该领域的布局虽整体比较早期,但也逐渐有“玩家”跑出。近期,云顶新耀就...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.